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Human cells are exposed to the electrophilic R,-unsaturated aldehyde acrolein from a variety of sources.
The reaction of acrolein with functionally critical protein thiol residues can yield important biological
consequences. Protein tyrosine phosphatases (PTPs) are an important class of cysteine-dependent enzymes
whose reactivity with acrolein previously has not been well-characterized. These enzymes catalyze the
dephosphorylation of phosphotyrosine residues on proteins via a phosphocysteine intermediate. PTPs
work in tandem with protein tyrosine kinases to regulate a number of critically important mammalian
signal transduction pathways. We find that acrolein is a potent time-dependent inactivator of the enzyme
PTP1B (kinact ) 0.02 ( 0.005 s-1 and KI ) 2.3 ( 0.6 × 10-4 M). The enzyme activity does not return
upon gel filtration of the inactivated enzyme, and addition of the competitive phosphatase inhibitor vanadate
slows inactivation of PTP1B by acrolein. Together, these observations suggest that acrolein covalently
modifies the active site of PTP1B. Mass spectrometric analysis reveals that acrolein modifies the catalytic
cysteine residue at the active site of the enzyme. Aliphatic aldehydes such as glyoxal, acetaldehyde, and
propanal are relatively weak inactivators of PTP1B under the conditions employed here. Similarly,
unsaturated aldehydes such as crotonaldehyde and 3-methyl-2-butenal bearing substitution at the alkene
terminus are poor inactivators of the enzyme. Overall, the data suggest that enzyme inactivation occurs
via conjugate addition of the catalytic cysteine residue to the carbon–carbon double bond of acrolein.
The results indicate that inactivation of PTPs should be considered as a possible contributor to the diverse
biological activities of acrolein and structurally related R,-unsaturated aldehydes.
Introduction
Human cells are exposed to the electrophilic R,-unsaturated
aldehyde acrolein from a variety of sources (1, 2). Acrolein can
be generated in the cell by endogenous lipid peroxidation (3–5)
and oxidation of amino acids (6) or introduced via dietary
sources (1), cigarette smoke (7), and the metabolism of drugs
(8–11) or other xenobiotics (12, 13). Acrolein displays a wide
range of biological activities (1, 2). One important chemical
reaction underlying the biological action of acrolein involves
covalent modification of cysteine thiol residues on proteins.
Specifically, reactions of acrolein with proteins that contain
functionally critical thiol side chains such as cysteine proteases
(caspase-3) (14–16), some ion channels (TRPA1) (17), and some
transcription factors (NF-κB, Keap1/Nrf2) (18, 19) have the
potential to yield significant biological effects.
Protein tyrosine phosphatases (PTPs) are an important class
of cysteine-dependent enzymes whose reactivity with acrolein
has not been well-characterized. These enzymes catalyze the
dephosphorylation of phosphotyrosine residues on proteins via
a phosphocysteine intermediate as shown in Scheme 1 (20–25).
PTPs work in tandem with protein tyrosine kinases to regulate
a number of critically important mammalian signal transduction
pathways (20–26). Not surprisingly, inhibition or inactivation
of PTPs has the potential to yield profound biological conse-
quences (27–32).
In the work reported here, we examined the kinetics and
mechanism of PTP inactivation by acrolein. We find that
acrolein is a potent irreversible inactivator of the enzyme
PTP1B. The data further suggest that the inactivation reaction
occurs via conjugate addition of the active site cysteine-215 to
the carbon–carbon double bond of acrolein.
Materials and Methods
Chemicals and Reagents. Reagents were purchased from the
following suppliers: buffer salts, p-nitrophenyl phosphate (pNPP),
thiols, trifluoroacetic acid (TFA), sodium orthovanadate, acetalde-
hyde, 3-methyl-2-butenal, and crotonaldehyde were obtained from
Sigma-Aldrich (St. Louis, MO). Catalase (catalog no. 106810) and
SOD (catalog no. 837113) were obtained from Roche Bioscience
(Palo Alto, CA). Acrolein and glyoxal were obtained from Acros
Organics. Sequencing grade modified trypsin (catalog no. V5111)
was obtained from Promega. Ammonium bicarbonate was obtained
from Fisher Scientific. Recombinant PTP1B (a.a. 1–322) was
prepared in our laboratory as reported previously (33). The
concentration of active PTP1B in the samples was determined as
described previously (33).
Time-Dependent Inactivation of PTP1B. Inactivation assays
were performed using modifications of existing literature protocols
(34–36). Free thiols were removed from a stock solution of purified
PTP1B using Zeba mini centrifugal buffer exchange columns
(Pierce, catalog no. 89882) according to the manufacturer’s protocol.
The exchange buffer contained 100 mM TRIS-HCl, 10 mM DTPA,
and 0.05% NP-40, pH 7.4. In the inactivation reactions, acrolein
was added as a stock solution in water to a mixture containing
PTP1B in Tris-HCl (100 mM), DTPA (10 mM), and NP-40 (0.05%
v/v) at 30 °C (final concentrations: acrolein, 20–60 µM; Tris-HCl,
50 mM; DTPA, 5 mM; NP-40, 0.025% v/v; and PTP1B, 75 nM).
Aliquots (10 µL) were removed at various time points (1, 2, and 5
min) and placed in 490 µL of PTP1B assay buffer consisting of
bis-Tris (50 mM, pH 6.0), NaCl (100 mM), DTPA (10 mM), and
pNPP (20 mM) at 30 °C for 10 min. The enzymatic reaction was
quenched by addition of NaOH (500 µL of a 2 N solution in water),
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and the amount of p-nitrophenol released during the assay was
determined at 25 °C by measuring the absorbance at 410 nm using
a UV–vis spectrometer.
Gel Filtration of Acrolein-Inactivated PTP1B. A solution of
acrolein in water (10 µL of 5 mM) was added to PTP1B [40 µL of
a 4 µM solution in Tris-HCl (100 mM), DTPA (10 mM), and NP-
40 (0.05% v/v)]. After 10 min, an aliquot (10 µL) was removed
and tested for activity to confirm that the enzyme was completely
inactivated. An aliquot of the remaining solution (12 µL) was gel
filtered through a Zeba micro spin column according to the
manufacturer’s protocol. The exchange buffer contained 100 mM
Tris-HCl, 10 mM NaCl, 10 mM DTPA, and 0.05% NP-40, pH
7.4. Following buffer exchange, a 10 µL aliquot was tested for
PTP1B activity as described above. No measurable return of PTP1B
activity was observed vs a control sample treated in an identical
manner except without inactivation by acrolein.
Time-Dependent Inactivation in the Presence of a
Competitive PTP1B Inhibitor or Superoxide Dismutase or
Catalase. An aliquot of thiol-free enzyme [20 µL of a 4 µM solution
in Tris-HCl (100 mM), DTPA (10 mM), and NP-40 (0.05% v/v)]
was combined with an aqueous solution of acrolein and orthovana-
date (20 µL of a mixture containing 500 µM acrolein and 1 mM
orthovanadate in water) at 25 °C (final concentrations: PTP1B, 2
µM; acrolein, 250 µM; orthovanadate, 500 µM; Tris-HCl, 50 mM;
DTPA, 5 mM; and NP-40, 0.025% v/v). After 5 min, a 10 µL
aliquot was removed and added to a cuvette containing a three-
component PTP1B assay buffer (990 µL) consisting of sodium
acetate (100 mM), bis-Tris (50 mM), Tris (50 mM), and pNPP (10
mM), at pH 7.0 (final volume of 1 mL). Immediately following
the addition of enzyme to the cuvette, the assay was mixed by
repeated inversion, and the enzyme catalyzed the release of
p-nitrophenol monitored at 25 °C by measuring the increase in
absorbance at 410 nm. Data points were taken every 2 s. In the
assays designed to probe the potential role of reactive oxygen
species in this inactivation process, acrolein (10 µL of a 100 mM
stock solution) was added to a cuvette containing the assay buffer
(985 µL of a mixture containing sodium acetate, 100 mM; bis-
Tris, 50 mM; Tris, 50 mM; pNPP, 10 mM, and either SOD, 10
µg/mL, or catalase, 0.5 µg/mL, at pH 7.0), followed by thiol-free
PTP1B (5 µL of a 4 µM solution in Tris-HCl, 100 mM; DTPA, 10
mM; and NP-40, 0.05% v/v). The PTP1B activity was then
monitored as described above. The presence of catalase or super-
oxide dismutase exerted no measurable effect on the inactivation
reaction.
Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight (MALDI TOF)/TOF MS and Nanospray MS/MS
Analysis of Acrolein-Modified PTP1B. A solution of acrolein (5
µL, 18 mM in water) was added to a solution containing thiol-free
PTP1B (45 µL of an approximately 14 pmol/µL solution in Tris-
HCl, 100 mM; NaCl, 10 mM; DTPA, 10 mM; and NP-40, 0.05%;
at pH 7.4), and the resulting mixture was incubated for 30 min at
25 °C. A control sample containing no acrolein was also prepared.
After incubation, both solutions were passed through a Zeba mini
centrifugal buffer exchange column. To the resulting mixtures,
sequence grade modified trypsin (50 µL of a 1 µg/50 µL solution
in 50 mM ammonium bicarbonate) was added. The digestion was
incubated at 37 °C for 18 h and then quenched with TFA (5 µL of
a 10% aqueous solution). An aliquot (20 µL) of each solution was
transferred to a microcentrifuge tube, frozen in liquid nitrogen, and
lyophilized to dryness. The residue was resuspended in water (10
µL) and again lyophilized. The final dried sample was reconstituted
in acetonitrile/water/88% formic acid (5 µL of 700/290/10 v/v/v).
For MALDI TOF/TOF MS analysis, a 0.6 µL portion of diluted
sample was mixed with an equal volume of R-cyano-4-hydroxy-
cinnamic acid (CHCA) matrix solution [5 mg CHCA/mL in 500/
455/20/25 (v/v/v/v) acetronitrile/water/10% TFA/400 mM aqueous
ammonium dihydrogen phosphate]. Aliquots (0.4 µL) of the mixture
were deposited on a polished stainless steel target. Crystallization
of the mixture proceeded under ambient conditions. Mass spectra
were acquired on an Applied Biosystems Inc. 4700 MALDI TOF/
TOF mass spectrometer with a 355 nm Nd:YAG laser (200 Hz) in
the positive ion-delayed extraction reflector MS mode. The MS
spectra (2000 laser shots summed/averaged) were acquired over
the mass range 700–4000 Da. Each MS spectrum was recalibrated
internally using the masses (monoisotopic [M + H]+) for the
PTP1B tryptic fragments observed at 1366.675 Da ([13–24]) and
2508.288 Da ([293–314]). For nanospray MS/MS of the active site
peptide 200–221, Ziptip (Millipore, standard C18) cleanup of
sample with fractions of 50/940/10, 100/890/10, and 200/790/10
(v/v/v) acetonitrile/water/88% formic acid (AWF) were pooled and
then lyophilized to dryness. The sample was reconstituted in 4 µL
of 700/290/10 AWF for nanospray QTOF MS analysis on an
Applied Biosystems/MDS Sciex (Foster City, CA) QStar/Pulsar/I
instrument fitted with a Proxeon (Odense, Denmark) nanospray
source. A pulsar frequency of 6.99 kHz was used for MS/MS mass
range 50–2000 Da. MS/MS spectra were obtained with N2 collision
gas. The MS/MS of the 3+ ion at 744.37 Da for the peptide of
interest was obtained with a collision energy of 35 V. The
instrument software was Analyst QS, and the data analysis software
was BioAnalyst 1.1.
Results
Kinetics of PTP1B Inactivation by Acrolein. We utilized
the catalytic subunit of human PTP1B (a.a. 1–322) as an
archetypal member of the PTP family of enzymes (20–25). We
find that acrolein is a potent time-dependent inactivator of
PTP1B (Figure 1A). A Kitz–Wilson replot of the inactivation
data (Figure 1B) reveals that the maximum rate of inactivation
at saturating concentrations of acrolein, kinact, is 0.02 ( 0.005
s-1, while the concentration of acrolein required to achieve a
half-maximal rate of inactivation, KI, is 2.3 ( 0.6 × 10-4 M.
It is worth noting that the apparent second-order rate constant
for inactivation of the enzyme by acrolein (kinact/KI ) 87 M-1
s-1) is comparable to that for hydrogen peroxide (10 M-1 s-1)
(37, 38), a known endogenous regulator of PTP1B activity
(39, 40). Inactivation of PTP1B by acrolein is not reversed by
gel filtration or dialysis to remove excess inactivator. This
observation, along with the time-dependent nature of the
reaction, indicates that the inactivation of PTP1B by acrolein
Scheme 1
1316 Chem. Res. Toxicol., Vol. 20, No. 9, 2007 Seiner et al.
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involves covalent modification of the enzyme. The inactivation
process is slowed by addition of the competitive PTP1B inhibitor
ortho vanadate (35) (Figure 2), thereby providing evidence that
the reaction is active site-directed.
Inactivation of PTP1B by Acrolein Does Not Involve
Reactive Oxygen Species. PTPs can be inactivated by reactive
oxygen species such as superoxide radical and hydrogen
peroxide (33, 37, 38). These agents inactivate PTP1B via
oxidation of the active site cysteine-215 to the sulfenic acid
oxidation state (38, 41–43). In the context of the current study,
it is important to note that spontaneous autooxidation of
aldehydes in aerobic solution has the potential to generate
superoxide radical and hydrogen peroxide (44). The possible
involvement of reactive oxygen species in the inactivation of
PTP1B by acrolein was ruled out by the observation that the
presence of the superoxide- and hydrogen peroxide-destroying
enzymes superoxide dismutase (SOD) and catalase (45) has no
effect on the rate of the inactivation reaction (data not shown).
Mass Spectrometry of Acrolein-Inactivated PTP1B. Ac-
rolein can covalently modify a number of amino acid residues
inproteins,includinghistidine,lysine,andcysteine(3,14–17,46–50).
Importantly, the active site of PTP1B contains both a cysteine
(Cys-215) and a histidine (His-216) residue that are required
for catalytic activity (51). Mass spectrometry was employed to
shed light on the site(s) at which acrolein covalently modifies
the active site of PTP1B. Toward this end, acrolein-inactivated
PTP1B was subjected to tryptic digestion and the resulting
fragments were analyzed by MALDI-TOF-TOF mass spec-
trometry. Signals for many of the expected (unmodified) tryptic
fragments of PTP1B were observed in the mass spectrum.
Importantly, a major signal was seen at m/z 2231.09 corre-
sponding to the acrolein-modified active site peptide a.a.
200–221. A very weak signal was observed for the unmodified
active site peptide (m/z 2175.17). In addition, weak signals were
detected, consistent with acrolein modification of four other
cysteine-containing tryptic fragments corresponding to a.a.
25–33 (m/z 1117.47), 80–103 (m/z 2920.38), 121–128 (m/z
1079.66), and 222–237 (m/z 1824.80). Nanospray MS/MS-TOF
was employed to further characterize the site(s) of acrolein
modification in the active site peptide a.a 200–221 (m/z 2231.09
[M + H]+). The masses for the b12-b15 ions are those expected
for the unmodified peptides (Figure 3). On the other hand, the
masses of the b16-b17 ions are increased by +56 Da, consistent
with modification of these fragment ions by acrolein. Similarly,
the masses for the y5 and y6 ions are consistent with those
expected for the unmodified peptide fragments, while the masses
for y7-y13 ions are increased by +56 Da. Overall, the data
indicate that acrolein inactivates PTP1B primarily via reaction
with the active site cysteine-215. Weak signals corresponding
to the acrolein-modified b15 and unmodified y7 ions are
observed, suggesting that some modification also occurs at
histidine-214 of the active site peptide.
Structure–Activity Studies with Related Aldehydes
Suggest That Acrolein Inactivates PTP1B via a
Conjugate Addition Mechanism. In aqueous solution, simple
thiols react with acrolein via initial conjugate addition to the
double bond of the R,-unsaturated aldehyde, rather than by
addition to the aldehyde moiety (52). Thus, we anticipated that
the inactivation of PTP1B by acrolein may proceed via the
conjugate addition mechanism shown in Scheme 2. Consistent
with this expectation, we find that aliphatic aldehydes such as
glyoxal, acetaldehyde, and propanal, lacking the unsaturation
found in acrolein, are relatively poor inactivators of the enzyme
(Table 1). These results are in line with previous work showing
that simple aldehydes such as acetaldehyde do not effectively
inactivate PTP1B (53). It is worth noting that more function-
alized peptidyl aldehydes that capture noncovalent binding
interactions with the enzyme active site are slow-binding,
reversible covalent inhibitors of protein tyrosine phosphatases
(54, 55). Also consistent with our favored conjugate addition
mechanism for the inactivation of PTP1B by acrolein, we find
that analogues such as crotonaldehyde and 3-methyl-2-butenal,
possessing steric bulk at the terminal position of the double
bond, are relatively weak inactivators of the enzyme (Table 1).
Discussion
Acrolein has previously been shown to inactivate a variety
of enzymes including DNA methyltransferase (46), protein
disulfide isomerase (49), glutathione reductase (47), caspase-3
(14–16), and carbonic anhydrase (48). In addition, modification
of ion channels (17) and transcription factors (18, 19) by acrolein
Figure 1. Semilog plot of time courses for the inactivation of PTP1B by various concentrations of acrolein (A) and Kitz–Wilson replot of the
inactivation data (B).
Figure 2. Inactivation of PTP1B by acrolein is slowed by the presence
of the competitive inhibitor orthovanadate.
InactiVation of a PTP by Acrolein Chem. Res. Toxicol., Vol. 20, No. 9, 2007 1317
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can alter their functional properties. Here, we provide evidence
that acrolein is a potent irreversible inactivator of the enzyme
PTP1B (kinact ) 0.02 ( 0.005 s-1, KI ) 2.3 ( 0.6 × 10-4 M).
The apparent second-order rate constant for the inactivation of
PTP1B by acrolein (87 M-1 s-1) is comparable to that reported
previously for hydrogen peroxide (10 M-1 s-1), a known
endogenous regulator of the enzyme (37–40). In general, our
findings mesh with previous reports that acrolein and structurally
related lipid peroxidation products inhibit PTP activity although,
in the earlier work, neither the kinetics nor the mechanism of
PTP inhibition by acrolein were elucidated (53, 56, 57). In our
study, mass spectrometry of the inactivated enzyme indicates
that the active site cysteine-215 residue is modified by acrolein.
Examination of a series of structurally related aldehydes further
shows that the double bond found in acrolein is central to its
properties as a phosphatase inactivator. This fact is revealed
by the observation that simple aliphatic aldehydes do not
inactivate PTP1B under the conditions employed for these
studies. Furthermore, steric bulk at the alkene terminus dimin-
ishes the PTP1B-inactivating properties of compounds in this
series. Together, these observations support an inactivation
Figure 3. ESI+-MS/MS analysis of the acrolein-modified PTP1B active site tryptic fragment, E200SGSLSPEHGPVVVHCSAGIGR221. Cysteine
215 is the active site nucleophile of PTP1B. Acrolein-modified fragment ions are denoted by an asterisk.
Scheme 2 Table 1. Inactivation of PTP1B by Various Aldehydes
a A solution containing PTP1B (225 nM) in sodium acetate (100
mM), bis-Tris (50 mM), Tris (50 mM), DETAPAC (5 mM), and DMF
(5% by volume), pH 7, was incubated with various aldehydes (500 µM)
at 25 °C. After 10 min, an aliquot (10 µL) was removed from the
solution and the fraction of remaining enzyme activity (vs a control
sample containing no aldehyde) was determined as described in the
Materials and Methods.
1318 Chem. Res. Toxicol., Vol. 20, No. 9, 2007 Seiner et al.
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mechanism involving conjugate addition of the active site
cysteine-215 to the carbon–carbon double bond of acrolein
(Scheme 2).
In conclusion, inactivation of PTPs can yield profound
biological consequences arising from the disruption of cellular
signaling pathways (27–32). The results reported here indicate
that inactivation of PTPs can be considered as a possible
contributor to the diverse biological activities (1, 2) of acrolein
and structurally related R,-unsaturated aldehydes.
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